Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Comparing the efficacy and safety of CT-P10 to rituximab in advanced stages follicular lymphoma

Christian Buske • 14 Jun 2017
ICML 2017
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Follicular Lymphoma Non-Hodgkin Lymphoma Rituximab

Christian Buske, MD from the University Hospital Ulm, Ulm, Germany discusses the Phase III trial comparing the efficacy and safety of the biosimilar CT-P10 to rituximab in combination with CVP in advanced follicular lymphoma (NCT02162771). The rationale of the study was to establish if the biosimilar is indeed similar to the originator. Prof. Buske further discusses the potential of using the biosimilar in diffuse large B-cell lymphoma (DLBCL) based on extrapolation.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland.
This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

More from Christian Buske

Looking to the future of B-cell lymphoma treatment
1:02
Looking to the future of B-cell lymphoma treatment
Christian Buske • 14 Jun 2025
The potential of translational research to impact the diagnosis & management of B-cell lymphomas
1:13
The potential of translational research to impact the diagnosis & management of B-cell lymphomas
Christian Buske • 14 Jun 2025
The OLYMP-1 trial: efficacy and safety of obinutuzumab monotherapy as a first-line treatment for MZL
2:03
The OLYMP-1 trial: efficacy and safety of obinutuzumab monotherapy as a first-line treatment for MZL
Christian Buske • 14 Jun 2025
Evolving treatment for WM: moving away from chemotherapy and toward fixed-duration combinations
2:12
Evolving treatment for WM: moving away from chemotherapy and toward fixed-duration combinations
Christian Buske • 6 Dec 2024

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals